• Home
  • News and Events

News and events

  • Email
  • Help

This section of the website contains the European Medicines Agency's news and press releases, information on meetings and events, public consultations and related information.

For a scrolling feed of all of the new and updated information published on the website, see the what's new page.

Latest news

This month's events

May 2016

M T W T F S S
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31
  • 30/05/2016 - 02/06/2016 : HMPC

    Committee for Herbal Medicinal Products (HMPC): 30 May – 2 June 2016

    The Committee on Herbal Medicinal Products (HMPC) is the committee that is responsible for preparing the Agency’s opinions on questions relating to herbal medicines.

  • 27/05/2016 - 27/05/2016 : EMA

    Multi-stakeholder advanced therapy medicinal products (ATMPs) expert meeting: exploring solutions to foster ATMPs’ development and patient access in Europe

    With representation from the European medicines regulatory network and the European Commission, EMA is organising this multi-stakeholder expert meeting on ATMPs to address challenges identified to pharmaceutical innovation in Europe. The aim is to understand the current European Union environment for ATMPs and to explore new or different ways for stimulating innovation, facilitating European research and development and accelerating patients’ access to high quality, safe and efficacious ATMPs. EMA has invited a broad range of experienced stakeholders involved throughout the ATMP medicines’ life cycle, from early research and development through to the product supply chain. This includes experienced academics, incubator managers, investors, healthcare professionals, patients, industry representatives (from micro-, small- and medium-sized as well as large companies) and health-technology-assessment bodies.

  • 25/05/2016 - 27/05/2016 : PDCO

    Paediatric Committee (PDCO): 25-27 May 2016

    The Paediatric Committee (PDCO) is the committee that is responsible for assessing the content of paediatric investigation plans, which describe how a medicine should be studied in children, as well as waivers and deferrals.

  • 23/05/2016 - 26/05/2016 : CHMP

    Committee for Medicinal Products for Human Use (CHMP): 23-26 May 2016

    The Committee for Medicinal Products for Human Use (CHMP) is the committee that is responsible for preparing the Agency's opinions on all questions concerning human medicines.

  • 18/05/2016 - 20/05/2016 : CAT

    Committee for Advanced Therapies (CAT): 18-20 May 2016

    The Committee for Advanced Therapies (CAT) is the committee that is responsible for assessing the quality, safety and efficacy of advanced-therapy medicines.

  • 17/05/2016 - 18/05/2016 : EMA

    EMA public workshop on extrapolation of efficacy and safety in medicine development

    In 2013, the European Medicines Agency (EMA) published a concept paper on extrapolation of efficacy and safety in medicine development. It aims to discuss the need and possibility of developing a framework for extrapolation approaches that are considered scientifically valid and reliable to support medicine authorisation. The framework will set out a structured approach for each extrapolation exercise, in order to improve interactions with stakeholders and to standardise decision making across committees. Further to the extrapolation expert meeting that took place in September 2015, EMA will publish a reflection paper on extrapolation across age groups that will include considerations specific to global product development and licensing of paediatric medicines. This workshop will present the reflection paper and seek feedback from developers.

  • 17/05/2016 - 19/05/2016 : CVMP

    Committee for Medicinal Products for Veterinary Use (CVMP): 17-19 May 2016

    The Committee for Medicinal Products for Veterinary Use (CVMP) is the committee that is responsible for preparing the Agency's opinions on all questions concerning veterinary medicines.

  • 17/05/2016 - 19/05/2016 : COMP

    Committee for Orphan Medicinal Products (COMP): 17-19 May 2016

    The Committee for Orphan Medicinal Products (COMP) is the committee that is responsible for reviewing applications for 'orphan medicinal product designation' for medicines intended for the diagnosis, prevention or treatment of rare diseases.

  • 10/05/2016 - 13/05/2016 : PRAC

    Pharmacovigilance Risk Assessment Committee (PRAC): 10-13 May 2016

    The Pharmacovigilance Risk Assessment Committee (PRAC) is the committee that is responsible for assessing all aspects of the risk management of medicines for human use.